A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Array BioPharma Inc
Start Date
October 31, 2019
End Date
June 29, 2021
Administered By
Duke Cancer Institute
Awarded By
Array BioPharma Inc
Start Date
October 31, 2019
End Date
June 29, 2021